Form 4: Mirum Pharmaceuticals Director Lon Cardon Reports Significant Equity Transactions

Mirum Pharmaceuticals, Inc. Director Lon Cardon has reported the acquisition of common stock, stock options, and restricted stock units, alongside the disposition of previously held restricted stock units, as detailed in a recent SEC Form 4 filing.

Summary

• Lon Cardon, a Director at Mirum Pharmaceuticals, Inc. (MIRM), reported several equity transactions on May 29, 2025.
• He acquired 5,703 shares of common stock through the exercise or conversion of derivative securities.
• Concurrently, 5,703 Restricted Stock Units (RSUs) were disposed of, which vested on the first anniversary of their grant date or the Issuer's 2025 annual stockholder meeting.
• Additionally, Mr. Cardon acquired 6,268 stock options with an exercise price of $44, which will vest on the first anniversary of their grant date or the Issuer's 2026 annual stockholder meeting and expire on May 28, 2035.
• He also acquired 3,977 new Restricted Stock Units, which will vest on the first anniversary of their grant date or the Issuer's 2026 annual stockholder meeting.

Sentiment

Score: 7

Explanation: The acquisition of new stock options and restricted stock units by a director, alongside the vesting of existing equity, generally signals continued alignment of interests with shareholders and potential confidence in the company's future, contributing to a moderately positive sentiment.

Positives

• The acquisition of additional stock options and restricted stock units by a director may indicate continued confidence in the company's future performance.
• The vesting of previously granted restricted stock units and their conversion to common stock represents a realization of equity compensation.

Future Outlook

The vesting schedules for the acquired stock options and restricted stock units extend into 2025 and 2026, indicating a long-term incentive structure for the director.

Industry Context

This filing is a routine disclosure of insider equity transactions, common across all publicly traded companies, and does not provide specific industry-wide insights.

Related Party Transactions

• The reported transactions involve equity compensation granted by Mirum Pharmaceuticals, Inc. to its director, Lon Cardon, which are considered related party transactions in the context of executive compensation.

Stakeholder Impact

• Shareholders may view the director's acquisition of additional equity as a positive signal of management's commitment and belief in the company's long-term prospects.
• Employees are not directly impacted by this specific filing, but executive compensation structures can influence overall company culture and morale.

Next Steps

• The acquired stock options will vest on the first anniversary of their grant date or the Issuer's 2026 annual stockholder meeting.
• The newly acquired restricted stock units will vest on the first anniversary of their grant date or the Issuer's 2026 annual stockholder meeting.

Key Dates

Recommendation

Keywords

Mirum Pharmaceuticals, MIRM, Lon Cardon, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Director Transactions, Share Acquisition, Vesting